One prospective randomized control trial in Denmark, SIRIRALS [44], aims to evaluate the systemic and peritoneal inflammatory response in RAS compared to LS for elective colonic cancer resections with a primary end point expressed as CRP and IL-6 between postoperative days 1–3 as well as LOS and conversion rate. The gene discussed is CRP; the disease is colonic neoplasm.